Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.
Shanghai Junshi Biosciences has approved a reduction of the registered capital in its joint venture with Immorna from RMB 100 million to RMB 2 million, maintaining equal ownership stakes. This strategic capital reduction aims to optimize resource allocation and improve fund utilization efficiency, without materially impacting the company’s operations or financial results.
For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.